Cyclosporin better than Artificial Tears for Ocular Rosacea

Written by on February 23, 2012 in Allergan, Ocular Rosacea with 0 Comments

restasis-cyclosporin
Skin and Allergy News has an article today highlighting the recent positive research into the usage of Cyclosporin as a treatment for Ocular Rosacea.

Dr. Harper mentions that she likes to include Oracea as an oral treatment for the worst of her ocular rosacea patients, but also uses 20mg twice a day of doxycycline for those who cannot afford Oracea. The point is made, that 50mg a day of doxycline does cross over the line to be no longer strictly subantimicrobial but anti-bacterial.

Interestingly also the point is made by Dr. Fowler that Cyclosporine is off-label when used to treat ocular rosacea, and may always be so. Dr. Fowler says that this is because ophthalmologists find it difficult to quantify ocular rosacea and indeed to distinguish it from dry eye. Thus the implication is that approval for Cyclosporine as a treatment for chronic dry eye serves as a `close-enough’ indication for ocular rosacea symptoms as well.

This article continues an ongoing series of articles, highlighted by Rosacea News, that reveals Restasis (Cyclosporine) as an Ocular Rosacea Treatment.

Topical Cyclosporine Proves Beneficial For Ocular Rosacea

By: BRUCE JANCIN, Skin & Allergy News Digital Network

WAIKOLOA, HAWAII – Topical cyclosporine 0.05% ophthalmic emulsion significantly outperformed artificial tears for the treatment of ocular rosacea in a double-blind, randomized, multicenter study.

“It’s a fairly small study, but I think it gives us some valuable information. This gives us a new option topically,” Dr. Julie C. Harper said in highlighting the study at the Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation (SDEF).

“People definitely felt better with this product than with artificial tears,” observed Dr. Harper, a dermatologist at the University of Alabama at Birmingham.

In addition, the topical cyclosporine group fared significantly better in the other study end points, which focused on eye dryness and tear production.

Also, tear break-up time (a measure of how quickly an eye becomes dry) increased by a mean of 3.56 seconds in the cyclosporine group, a significantly more favorable effect than the 0.04-second decrease in the artificial tears arm.

The investigators speculated that topical cyclosporine’s clinical benefits in ocular rosacea are due to the drug’s anti-inflammatory effects, including a cyclosporine-mediated reduction in the number of activated lymphocytes in the conjunctiva, in combination with stimulation of increased tear production.

[Dr. Fowler disclosed that he has received research grants from Allergan, which markets Restasis. He also serves as a consultant to Galderma, which markets Oracea, as well as to numerous other pharmaceutical companies. Dr. Harper is on the speakers bureaus for Allergan, Galderma, and a handful of other companies.]

Related Articles

 

Read more about: Allergan, Ocular Rosacea

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.